University Hospital Cologne (CIO): Cancer Care in Germany

CIO Cologne developed around the integration of cancer services and research within a university hospital. Its role is to connect disciplines that might otherwise assess a patient separately, supporting coordinated diagnosis and treatment planning rather than functioning as one standalone ward or clinic.

Today, it participates in the Center for Integrated Oncology collaboration across Aachen, Bonn, Cologne and Düsseldorf. This regional structure links academic oncology expertise, but patients should distinguish the Cologne service from the wider network: an intervention or study associated with the collaboration may be delivered at another site.

The centre operates within a large university hospital, giving oncology teams access to specialist medical, surgical, diagnostic and supportive services. A single bed count would not adequately describe the CIO’s size because cancer care is distributed across departments and outpatient settings. Its research portfolio provides another indication of its scope, although study counts change.

It is particularly associated with integrated care, lung cancer networking and molecular diagnostics, alongside lymphoma and cellular therapy programmes. These features describe its clinical and research focus; they do not establish that it is the best option for an individual patient or imply superior outcomes.

Lung cancer is a notable focus, including participation in national network activity linking molecular testing with treatment decisions. For appropriate patients, tumour testing can identify alterations relevant to targeted medicines or study eligibility. The usefulness of testing depends on the cancer subtype, available tissue, previous results and the treatment setting.

Blood cancer services include lymphoma programmes and assessment for CAR-T therapy in selected indications. Different leukaemias, lymphomas and related diseases require distinct pathways, so patients should seek review by the team responsible for their exact diagnosis rather than request a treatment in isolation.

Breast, colon and liver cancers are also included in the centre’s specialty profile. Management may combine local treatments and systemic therapy, with decisions influenced by stage and tumour biology. For liver disease, the team must distinguish a primary liver cancer from cancer that has spread to the liver, as treatment pathways differ.

Surgery and radiation therapy are among the available treatment modalities. Their roles may include treatment with curative intent, reducing the risk of recurrence or relieving symptoms. Suitability depends on tumour location, extent of disease, previous treatment and overall health; a referral does not automatically mean that an operation or radiation course will be recommended.

Systemic options include immunotherapy and targeted therapy, alongside established drug treatments where appropriate. Immunotherapy is useful in some cancers and treatment settings, while targeted medicines generally require a relevant biological feature. Neither approach is universally effective, and both can cause significant adverse effects requiring monitoring.

CAR-T therapy uses a patient’s modified immune cells to target particular cancer cells. At Cologne, it is relevant to selected blood cancer pathways. Assessment includes the exact diagnosis, previous therapies, current health and whether an approved indication or suitable trial applies. Treatment involves preparation and close monitoring, with potentially serious complications.

Clinical trials may provide access to investigational approaches, but participation is not necessarily preferable to standard treatment. Multidisciplinary review can help establish the sequence of available options. International patients should also discuss symptom control, rehabilitation and supportive or palliative care needs, including how these will be managed after returning home.

The supplied centre profile describes around 350 active oncology clinical trials. This figure is indicative: portfolios change, and 'active' can include studies that are following existing participants rather than enrolling new ones. Patients should ask whether a quoted total refers specifically to Cologne or to a broader network, and request information about studies relevant to their diagnosis.

Trial screening usually requires detailed pathology, staging, previous treatment information, current health assessments and, for some studies, molecular results. Eligibility criteria may specify prior therapies, organ function or particular tumour alterations. A promising initial match does not guarantee enrolment, since screening results and available places also matter.

International patients should ask the appropriate clinical team for a records-based assessment before travel. Confirm the trial location, visit schedule, language requirements, emergency arrangements and responsibilities for costs. Participation requires informed consent, and research-specific funding should not be assumed to cover routine care, accommodation or travel.

Start by asking the hospital which service handles international oncology referrals and whether a preliminary document review is possible. Explain the exact diagnosis, current treatment and reason for seeking care abroad. Request clarification of what additional assessment would be needed and whether it could realistically change management; avoid interrupting effective treatment while awaiting a response.

Before booking travel, obtain confirmation of the appointment or admission, the proposed assessment plan and financial arrangements. Identify who will provide care if complications occur after discharge and who will communicate with your home oncologist. Treatment involving repeated visits or close monitoring may require an extended local stay and a companion, depending on the clinical plan.

Contact details below come from the hospital's own published international patient information.

Location: Cologne, Germany

Email: ipo@uk-koeln.de

Phone: +49 221 478 0

Website: https://www.uk-koeln.de

Languages supported: German, English, Russian, Arabic

Remote second opinion: Available

Always confirm current contact details on the hospital's own website before sending medical records, and never send documents to an address you have not verified.